# Meyling h Cheok

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6138096/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 90 papers | 5,376 citations | 136950 32 h-index | 85541 71 g-index |
| 96 all docs | 96 docs citations | 96 times ranked | 7307 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncology, The, 2009, 10, 125-134. | 10.7 | 826 |
| 2 | A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 2016, 540, 433-437. | 27.8 | 617 |
| 3 | Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment. New England Journal of Medicine, 2004, 351, 533-542. | 27.0 | 565 |
| 4 | TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291. | 1.4 | 264 |
| 5 | Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genetics, 2003, 34, 85-90. | 21.4 | 239 |
| 6 | Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nature Reviews Cancer, 2006, 6, 117-129. | 28.4 | 205 |
| 7 | Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2009, 85, 164-172. | 4.7 | 196 |
| 8 | Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell, 2005, 7, 375-386. | 16.8 | 150 |
| 9 | Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nature Medicine, 2011, 17, 1298-1303. | 30.7 | 133 |
| 10 | Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117. | 8.2 | 129 |
| 11 | The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood, 2006, 107, 769-776. | 1.4 | 126 |
| 12 | Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research, 2008, 68, 4983-4989. | 0.9 | 124 |
| 13 | Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135. | 1.4 | 121 |
| 14 | A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nature Medicine, 2022, 28, 1212-1223. | 30.7 | 104 |
| 15 | Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?. American Journal of Obstetrics and Gynecology, 2002, 187, 333-339. | 1.3 | 102 |
| 16 | IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353. | 1.8 | 92 |
| 17 | Thiopurine pathway. Pharmacogenetics and Genomics, 2010, 20, 573-574. | 1.5 | 89 |
| 18 | In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83. | 8.4 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene, 2019, 38, 7146-7165. | 5.9 | 75 |
| 20 | Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Journal of Immunology, 2015, 195, 2580-2590. | 0.8 | 68 |
| 21 | Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546. | 1.4 | 62 |
| 22 | The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2008, 100, 1792-1803. | 6.3 | 61 |
| 23 | Pharmacogenetics in Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 39-51. | 3.4 | 55 |
| 24 | Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood, 2005, 106, 1778-1785. | 1.4 | 53 |
| 25 | Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 2014, 5, 916-932. | 1.8 | 47 |
| 26 | The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357. | 7.2 | 44 |
| 27 | Neurofibromatosisâ€1 gene deletions and mutations in de novo adult acute myeloid leukemia. American Journal of Hematology, 2013, 88, 306-311. | 4.1 | 43 |
| 28 | Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441. | 1.4 | 38 |
| 29 | Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. Human Molecular Genetics, 2007, 16, 2261-2271. | 2.9 | 38 |
| 30 | PHARMACOGENOMICS OF ACUTE LEUKEMIA. Annual Review of Pharmacology and Toxicology, 2006, 46, 317-353. | 9.4 | 37 |
| 31 | CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer Research, 2015, 75, 3902-3911. | 0.9 | 36 |
| 32 | Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. British Journal of Cancer, 2006, 94, 93-100. | 6.4 | 35 |
| 33 | Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551. | 5.2 | 35 |
| 34 | Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia, 2017, 31, 555-564. | 7.2 | 34 |
| 35 | Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Reports, 2020, 30, 739-754.e4. | 6.4 | 32 |
| 36 | Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes and Cancer, 2005, 42, 107-116. | 2.8 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica, 2021, 106, 3056-3066. | 3.5 | 28 |
| 38 | Activity of Ladanein on Leukemia Cell Lines and Its Occurrence inMarrubium vulgare. Planta Medica, 2010, 76, 86-87. | 1.3 | 27 |
| 39 | Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers, 2019, 11, 1323. | 3.7 | 26 |
| 40 | Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood, 2017, 129, 484-496. | 1.4 | 22 |
| 41 | Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood, 2006, 108, 1984-1990. | 1.4 | 20 |
| 42 | Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia, 2010, 24, 1386-1388. | 7.2 | 20 |
| 43 | Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences, 2020, 21, 5626. | 4.1 | 20 |
| 44 | Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget, 2016, 7, 62377-62385. | 1.8 | 20 |
| 45 | Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget, 2016, 7, 2889-2909. | 1.8 | 19 |
| 46 | Genetic polymorphisms in <scp>ARID</scp>5B,<scp>CEBPE</scp>,<scp>IKZF</scp>1 and <scp>CDKN</scp>2A in relation with risk of acute lymphoblastic leukaemia in adults: a <scp>G</scp>roup for <scp>R</scp>esearch on <scp>A</scp>dult <scp>A</scp>cute <scp>L</scp>ymphoblastic <scp>L</scp>eukaemia (GRAALL) study. British Journal of Haematology, 2012, 159, 599-613. | 2.5 | 18 |
| 47 | Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics, 2009, 10, 1839-1851. | 1.3 | 17 |
| 48 | Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233. | 12.8 | 17 |
| 49 | Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117. | 8.2 | 16 |
| 50 | Promoter Polymorphisms in the Î²-2 Adrenergic Receptor Are Associated With Drug-Induced Gene Expression Changes and Response in Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2010, 88, 854-861. | 4.7 | 15 |
| 51 | Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. Expert Opinion on Therapeutic Targets, 2021, 25, 299-309. | 3.4 | 15 |
| 52 | Classification of <scp>CEBPA</scp> mutated acute myeloid leukemia by <scp>GATA2</scp> mutations. American Journal of Hematology, 2015, 90, E93-4. | 4.1 | 12 |
| 53 | Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Advances, 2020, 4, 5322-5335. | 5.2 | 8 |
| 54 | Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. Journal of Visualized Experiments, 2018, , . | 0.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). Leukemia Research, 2017, 56, 21-28. | 0.8 | 6 |
| 56 | Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. Leukemia, 2022, 36, 656-663. | 7.2 | 6 |
| 57 | Identification of Gene Expression Profiles in Acute Lymphoblastic Leukemia Cells That Discriminate Intracellular Thioguanine Nucleotide Accumulation in ALL Cells after In Vivo Treatment with Mercaptopurine.. Blood, 2004, 104, 453-453. | 1.4 | 5 |
| 58 | Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. International Journal of Molecular Sciences, 2022, 23, 5555. | 4.1 | 5 |
| 59 | Expression arrays illuminate a way forward for mantle cell lymphoma. Cancer Cell, 2003, 3, 100-102. | 16.8 | 4 |
| 60 | Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88. | 3.7 | 4 |
| 61 | Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163. | 1.4 | 4 |
| 62 | A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. Oncotarget, 2018, 9, 33869-33870. | 1.8 | 4 |
| 63 | High-dose Methotrexate: The Rationaleâ€¦. Journal of Pediatric Hematology/Oncology, 2009, 31, 224-225. | 0.6 | 3 |
| 64 | Pharmacogenomic considerations of xenograft mouse models of acute leukemia. Pharmacogenomics, 2012, 13, 1759-1772. | 1.3 | 3 |
| 65 | Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. Blood Advances, 2022, 6, 2773-2777. | 5.2 | 3 |
| 66 | Ex vivo drug sensitivity profilingâ€guided treatment of a relapsed pediatric mixedâ€phenotype acute leukemia with venetoclax and azacitidine. Pediatric Blood and Cancer, 2022, 69, e29678. | 1.5 | 3 |
| 67 | New-generation sequencing (NGS) in hematologic oncology laboratories. Hematologie, 2013, 19, 112-122. | 0.0 | 2 |
| 68 | MPAgenomics: an R package for multi-patient analysis of genomic markers. BMC Bioinformatics, 2014, 15, 394. | 2.6 | 2 |
| 69 | A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients. Blood, 2018, 132, 2765-2765. | 1.4 | 2 |
| 70 | Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 3932-3932. | 1.4 | 2 |
| 71 | Antileukemic drug effects in childhood acute lymphoblastic leukemia. Expert Review of Clinical Pharmacology, 2008, 1, 401-413. | 3.1 | 1 |
| 72 | Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy. EJHaem, 2021, 2, 196-210. | 1.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327. | 1.4 | 1 |
| 74 | Impact of CNA on AML prognosis. Oncotarget, 2018, 9, 12540-12541. | 1.8 | 1 |
| 75 | C020 Prevalence of TET2 mutations in MDS. Leukemia Research, 2009, 33, S43-S44. | 0.8 | 0 |
| 76 | Folate Pathway Gene Expression Differs in Genetic Subtypes of Acute Lymphoblastic Leukemia and Influences Methotrexate Pharmacodynamics.. Blood, 2004, 104, 452-452. | 1.4 | 0 |
| 77 | Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. Blood, 2004, 104, 1959-1959. | 1.4 | 0 |
| 78 | Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 477-477. | 8.2 | 0 |
| 79 | Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.. Blood, 2007, 110, 2827-2827. | 1.4 | 0 |
| 80 | Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171. | 1.4 | 0 |
| 81 | SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group. Blood, 2011, 118, 2533-2533. | 1.4 | 0 |
| 82 | DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.. Blood, 2012, 120, 2392-2392. | 1.4 | 0 |
| 83 | Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics. Blood, 2014, 124, 2324-2324. | 1.4 | 0 |
| 84 | Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360. | 1.4 | 0 |
| 85 | TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy. Blood, 2014, 124, 68-68. | 1.4 | 0 |
| 86 | Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. Blood, 2014, 124, 1007-1007. | 1.4 | 0 |
| 87 | Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2016, 128, 3153-3153. | 1.4 | 0 |
| 88 | Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC). Blood, 2018, 132, 4009-4009. | 1.4 | 0 |
| 89 | Acromio-humeral Interval during Elevation when Supraspinatus is Deficient. IFMBE Proceedings, 2009, , 2110-2113. | 0.3 | 0 |
| 90 | Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network. Blood, 2021, 138, 2375-2375. | 1.4 | 0 |